Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification

Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification

BackgroundPrimary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer (NSCLC). Currently, anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) has become an important treatment for NSCLC. Anti-human PD-1 monoclonal antibodies, such as nivolumab,...

Full description

Bibliographic Details
Main Authors: Yanyang Liu, Lang Long, Jiewei Liu, Lingling Zhu, Feng Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
pulmonary lymphoepithelioma-like carcinoma
FGFR3
anlotinib
nivolumab
anti-PD-1 resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.749682/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.749682/full

Similar Items